The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations

Snake Envenomation Clinical Trial

Official title:

The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00303303
• Other study ID #: 06-01-12B
• Status: Terminated
• Phase: Phase 4
• Start date: April 2005
• Est. completion date: May 2008

Study information

• Verified date: August 2013
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Most patients bitten by copperhead snakes do not currently receive antivenom. Some snakebite victims have long term problems with the function of the limb that was bitten. This study will determine whether early administration of antivenom to patients with mild to moderate copperhead snakebites reduces long-term complications.

Description:

This study seeks to answer three important questions about the role of ovine (sheep-derived) antivenom in the treatment of people bitten by copperhead snakes (Agkistrodon contortrix):

1. Although ovine antivenom has been approved by the FDA for treatment of copperhead envenomation, copperhead victims were excluded from the previous clinical trials. Animal experiments and retrospective human data suggest that the antivenom probably does work for copperhead snakebite, at least in the short term. This study will determine whether the antivenom is actually effective in reducing pain, swelling, and other immediate effects of copperhead snakebite.

2. Deaths from copperhead snakebite are extremely rare, but survivors often report long term problems with pain and swelling in the envenomated limb. No study has formally measured the long-term outcomes in untreated snakebite, nor whether antivenom has any benefit in reducing the duration or severity of these complications. This study will answer this question through formal assessments of limb function up to 12 months after treatment.

3. After initial control of the signs and symptoms of snakebite is achieved with antivenom therapy, some patients develop recurrent swelling or blood clotting problems. A randomized controlled trial in rattlesnake victims showed that the frequency of these problems is reduced by administration of 6 additional vials of antivenom over 18 hours ("maintenance therapy"). However, blood clotting problems are uncommon in copperhead snakebite even without antivenom treatment, and a retrospective trial suggested that maintenance therapy may have no effect on the frequency of delayed swelling in copperhead victims. In the typical copperhead victim, maintenance therapy increases the cost of treatment by more than 100%. This study will determine whether maintenance therapy is necessary in mild to moderate copperhead snakebite.

Patients are eligible for enrollment if they have been bitten by a snake positively identified as a copperhead within 6 hours of enrollment, if they have signs of mild or moderate severity envenomation, and if contraindications are not present.

After appropriate informed consent, patients are randomized to receive:

A. initial stabilizing dose of antivenom, followed by maintenance therapy,

B. initial stabilizing dose of antivenom followed by placebo in lieu of maintenance therapy, or

C. placebo for both initial dose and maintenance.

All laboratory testing, pain medication, hospitalization, and other therapies are standard for snakebite of this severity. If at any time the envenomation becomes severe, antivenom is administered.

In addition to the standard assessments performed on all snakebite victims (swelling, pain, vital signs, blood clotting, complications of therapy), patients in this study receive formal assessments of the function of the envenomated limb. This assessment uses the AMA disability rating system and the American Academy of Orthopedic Surgeons' Normative Outcomes Study questionnaire do determine how well the limbs function and how well the limbs perform and how much any remaining problems interfere with the patients' long-term happiness and ability to perform common activities of daily living.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months and older

Eligibility

Inclusion Criteria:

• Envenomation by copperhead snake (Agkistrodon contortrix) within 6 hours

• Mild or moderate severity envenomation

Exclusion Criteria:

• Allergy to antivenom or components

• Severe envenomation (hypotension, severe swelling, compartment syndrome, bleeding, etc.)

• Uncertain snake ID

• Prior treatment with antivenom

Related Conditions & MeSH terms

• Poisoning
• Snake Bites
• Snake Envenomation

Intervention

Biological:
• Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)
Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
• Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)
Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
• Placebo
Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.

Locations

Country	Name	City	State
United States	Carolinas Medical Center	Charlotte	North Carolina
United States	Richland Memorial Hospital	Columbia	South Carolina
United States	Duke University Medical Center	Durham	North Carolina
United States	Medical College of Virigina/Virginia Commonwealth University Hospital	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Limb Function: AMA Disability Rating Score of Envenomated Limb	The range of possible scores is 0 - 100, and a lower score denotes less disability.	14 days
Primary	Limb Function: AAOS Normative Outcome Study Scoring for Envenomated Limb	Score ranges from 0-100 with higher scores meaning better function.	14 days
Primary	Limb Function: AAOS Normative Outcome Study Scoring for Envenomated Limb	Score ranges from 0-100 with higher scores meaning better function.	One year
Primary	Limb Function: AAOS--time to Return to Normal Value	Score ranges from 0-100 with higher scores meaning better function. Time in days to return to baseline value.	14 days
Secondary	Pain: Visual Analog Score	0-100 mm visual analog scale. Lower scores mean less pain.	14 days
Secondary	Pain Medication Use	Mg of morphine equivalents	First 6 hours from baseline, first 18 hours from baseline, First 24 hours from baseline, 12 months
Secondary	Swelling: Percentage (%) of Limb Spread Proximal From Bite Site		12 months
Secondary	Swelling: % Change in Volume Compared to Contralateral (Non-envenomated) Limb		14 days
Secondary	Limb Function: Return to Work		Week 4
Secondary	Limb Function: Physical or Occupational Therapy Sessions Attended		Week 4
Secondary	Hematological: Clotting Studies and Platelet Counts		12 months
Secondary	Complications of Therapy	Number of participants with acute hypersensitivity reactions	12 months